Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.
Stein RC, Dunn JA, Bartlett JM, Campbell AF, Marshall A, Hall P, Rooshenas L, Morgan A, Poole C, Pinder SE, Cameron DA, Stallard N, Donovan JL, McCabe C, Hughes-Davies L, Makris A; OPTIMA Trial Management Group. Stein RC, et al. Health Technol Assess. 2016 Feb;20(10):xxiii-xxix, 1-201. doi: 10.3310/hta20100. Health Technol Assess. 2016. PMID: 26867046 Free PMC article. Clinical Trial.
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.
Bartlett JM, Bayani J, Marshall A, Dunn JA, Campbell A, Cunningham C, Sobol MS, Hall PS, Poole CJ, Cameron DA, Earl HM, Rea DW, Macpherson IR, Canney P, Francis A, McCabe C, Pinder SE, Hughes-Davies L, Makris A, Stein RC; OPTIMA TMG. Bartlett JM, et al. J Natl Cancer Inst. 2016 Apr 29;108(9):djw050. doi: 10.1093/jnci/djw050. Print 2016 Sep. J Natl Cancer Inst. 2016. PMID: 27130929 Free PMC article. Clinical Trial.
Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial.
Hall PS, Smith A, Hulme C, Vargas-Palacios A, Makris A, Hughes-Davies L, Dunn JA, Bartlett JMS, Cameron DA, Marshall A, Campbell A, Macpherson IR, Dan Rea, Francis A, Earl H, Morgan A, Stein RC, McCabe C; OPTIMA Trial Management Group. Hall PS, et al. Among authors: hughes davies l. Value Health. 2017 Dec;20(10):1311-1318. doi: 10.1016/j.jval.2017.04.021. Epub 2017 Jul 11. Value Health. 2017. PMID: 29241890 Free article. Clinical Trial.
Strategies to Improve Recruitment to a De-escalation Trial: A Mixed-Methods Study of the OPTIMA Prelim Trial in Early Breast Cancer.
Conefrey C, Donovan JL, Stein RC, Paramasivan S, Marshall A, Bartlett J, Cameron D, Campbell A, Dunn J, Earl H, Hall P, Harmer V, Hughes-Davies L, Macpherson I, Makris A, Morgan A, Pinder S, Poole C, Rea D, Rooshenas L; OPTIMA Prelim Study Group. Conefrey C, et al. Among authors: hughes davies l. Clin Oncol (R Coll Radiol). 2020 Jun;32(6):382-389. doi: 10.1016/j.clon.2020.01.029. Epub 2020 Feb 20. Clin Oncol (R Coll Radiol). 2020. PMID: 32089356 Free PMC article.
Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial.
Bartlett J, Canney P, Campbell A, Cameron D, Donovan J, Dunn J, Earl H, Francis A, Hall P, Harmer V, Higgins H, Hillier L, Hulme C, Hughes-Davies L, Makris A, Morgan A, McCabe C, Pinder S, Poole C, Rea D, Stallard N, Stein R. Bartlett J, et al. Clin Oncol (R Coll Radiol). 2013 Feb;25(2):109-16. doi: 10.1016/j.clon.2012.10.005. Epub 2012 Dec 23. Clin Oncol (R Coll Radiol). 2013. PMID: 23267818 Review.
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.
Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Abraham J, Thomas J, Provenzano E, Hughes-Davies L, Gounaris I, McAdam K, Chan S, Ahmad R, Hickish T, Houston S, Rea D, Bartlett J, Caldas C, Cameron DA, Hayward L; ARTemis Investigators. Earl HM, et al. Lancet Oncol. 2015 Jun;16(6):656-66. doi: 10.1016/S1470-2045(15)70137-3. Epub 2015 May 11. Lancet Oncol. 2015. PMID: 25975632 Free article. Clinical Trial.
Trastuzumab-associated cardiac events in the Persephone trial.
Earl HM, Vallier AL, Dunn J, Loi S, Ogburn E, McAdam K, Hughes-Davies L, Harnett A, Abraham J, Wardley A, Cameron DA, Miles D, Gounaris I, Plummer C, Hiller L. Earl HM, et al. Br J Cancer. 2016 Dec 6;115(12):1462-1470. doi: 10.1038/bjc.2016.357. Epub 2016 Nov 22. Br J Cancer. 2016. PMID: 27875516 Free PMC article. Clinical Trial.
Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial.
Thomas JSJ, Provenzano E, Hiller L, Dunn J, Blenkinsop C, Grybowicz L, Vallier AL, Gounaris I, Abraham J, Hughes-Davies L, McAdam K, Chan S, Ahmad R, Hickish T, Houston S, Rea D, Caldas C, Bartlett JM, Cameron DA, Hayward RL, Earl HM. Thomas JSJ, et al. Mod Pathol. 2017 Aug;30(8):1069-1077. doi: 10.1038/modpathol.2017.30. Epub 2017 May 26. Mod Pathol. 2017. PMID: 28548129 Free article.
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.
Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Gounaris I, Abraham JE, Hughes-Davies L, McAdam K, Chan S, Ahmad R, Hickish T, Rea D, Caldas C, Bartlett JMS, Cameron DA, Provenzano E, Thomas J, Hayward RL; ARTemis Investigators Group. Earl HM, et al. Ann Oncol. 2017 Aug 1;28(8):1817-1824. doi: 10.1093/annonc/mdx173. Ann Oncol. 2017. PMID: 28459938 Free PMC article. Clinical Trial.
53 results